Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Norway
  4. Oslo Bors
  5. BerGenBio ASA
  6. Company
    BGBIO   NO0010650013

BERGENBIO ASA

(BGBIO)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Business Summary
Bergenbio ASA is Norway-based company that provides technology platforms used in the research and pre-clinical development of drug targets, associated biomarkers and therapeutics for the treatment of cancer. The Company's business portfolio comprises such development stage products as oral axillary lymphoscintigraphy (AXL) kinase inhibitors, small molecule AXL inhibitors, and antibody programs. Its flagship product is BGB324, an orally avaliable small molecule AXL kinase inhibitor. Inhibition of AXL kinase activity addresses an important mechanism in the evolution of cancer cell in terms of its aggressiveness, and focuses on creation of therapeutic options for cancer patients. The Company also performs a range of clinical trials for interested patients, primarily affected with acute myeloid leukemia and non-small cell lung cancer.
Sales per Business
20192020Delta
Biopharmaceutical8.90100%0.60100% -93.25%
NOK in Million
Sales per region
20192020Delta
Norway8.90100%0.60100% -93.25%
NOK in Million
Managers
Name Title Age Since
Martin Olin Chief Executive Officer 51 2021
Rune Skeie Chief Financial Officer 47 2021
Alison Messom, Dr. Director-Clinical Operations 48 2019
E. Gwyn Thomas, Dr. Chief Medical Officer - -
Nigel McCracken, Dr. Chief Scientific Officer - 2021
Gro Gausdal, Dr. Director of Research - 2013
James Barnes, Dr. Operations Director - -
Stener Kvinnsland, Dr. Independent Non-Executive Director 72 2015
Hani Gabra Director-Clinical Development - 2021
Debbie Molyneux Director-Human Resources - 2019
Members of the board
Name Title Age Since
Sveinung Hole Chairman 53 2019
Stener Kvinnsland, Dr. Independent Non-Executive Director 72 2015
Debra Stephanie Barker, Dr. Non-Executive Director 58 2019
Sally Bennett, Dr. Non-Executive Director - -
François Thomas, Dr. Non-Executive Director 62 -
Equities
Vote QuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 88,247,755 50,723,830 57.5% 0 0.0% 57.5%
Shareholders
NameEquities%
Trond Mohn 23,254,958 26.3%
Investinor AS 7,270,780 8.23%
Nordea Investment Management AB (Norway) 6,331,606 7.16%
Fjärde AP-fonden 4,487,493 5.08%
Alfred Berg Kapitalforvaltning AS 3,793,133 4.29%
Sarsia Seed Management AS 2,117,900 2.40%
Magne Roar Sangolt 1,712,426 1.94%
Marit Mohn 1,700,000 1.92%
MP Pensjon PK 1,572,983 1.78%
KLP Kapitalforvaltning AS 1,540,000 1.74%
Company contact information
BerGenBio ASA
Jonas Lies Vei 91
Bergen, Hordaland 5009

Phone : +47.53.50.15.64
Web : http://www.bergenbio.com
Brand Portfolio
In partnership withAllbrands.markets
More brands of BerGenBio ASA
Sector Bio Therapeutic Drugs